Protocol I6T- MC-AMBE  
 
A Safety, Tolerability, and Pharmacokinetic Study of Injections of LY3074828 Solution Using Investigational 1 -mL Pre -filled Syringes and Investigational 1- mL Autoinjector in Healthy  
Subjects  
 [STUDY_ID_REMOVED]  Approval Date: 17- Dec-2018
 
I 6 T -M C -A M B E Cli ni c al P h ar m a c ol o g y Pr ot o c ol P a g e 1
LY 3 0 7 4 8 2 8 Pr ot o c ol I 6 T -M C -A M B E 
A S af et y , T ol er a bilit y , a n d P h ar m a c o ki n eti c St u d y  of 
I nj e cti o n s of L Y 3 0 7 4 8 2 8 S ol uti o n U si n g I n v e sti g ati o n al 
1- m L Pr e -fill e d S y ri n g e sa n d I n v e sti g ati o n al 
1- m L A u t oi nj e ct or i n H e alt h y  S u bj e ct s 
C o nfi d e nti al I nf or m ati o n 
T h e i nf or m ati o n c o nt ai n e d i n t hi s pr ot o c ol i s c o nfi d e nti al a n d i s i nt e n d e d f or t h e u s e of 
cli ni c al i n v e sti g at or s.  It i s t h e pr o p ert y of Eli Lill y a n d C o m p a n y or it s s u b si di ari e s a n d 
s h o ul d n ot b e c o pi e d b y or di stri b ut e d t o p er s o n s n ot i n v ol v e d i n t h e cli ni c al i n v e sti g ati o n of 
L Y 3 0 7 4 8 2 8 , u nl e s s s u c h p er s o n s ar e b o u n d b y a c o nfi d e nti alit y a gr e e m e nt wit h Eli Lill y 
a n d C o m p a n y or it s s u b si di ari e s. 
N ot e t o R e g ul at or y A ut h oriti e s:   T hi s d o c u m e nt m a y c o n t ai n pr ot e ct e d p er s o n al d at a 
a n d/ or c o m m er ci all y c o nfi d e nti al i nf or m ati o n e x e m pt fr o m p u bli c di s cl o s ur e.  Eli Lill y a n d 
C o m p a n y r e q u e st s c o n s ult ati o n r e g ar di n g r el e a s e/r e d a cti o n pri or t o a n y p u bli c r el e a s e.  I n 
t h e U nit e d St at e s, t hi s d o c u m e nt i s s u bj e ct t o Fr e e d o m of I nf or m ati o n A ct ( F OI A) 
E x e m pti o n 4 a n d m a y n ot b e r e pr o d u c e d or ot h er wi s e di s s e mi n at e d wit h o ut t h e writt e n 
a p pr o v al of Eli Lill y a n d C o m p a n y or it s s u b si di ari e s. 
A p pr o v al D at e: 1 7- D e c- 2 0 1 8 G M T L Y 3 0 7 4 8 2 8 
Eli Lill y a n d C o m p a n y 
I n di a n a p oli s, I n di a n a U S A 4 6 2 8 5 
Cli ni c al P h ar m a c ol o g y Pr ot o c ol El e ctr o ni c all y Si g n e d a n d A p pr o v e d b y Lill y o n d at e 
pr o vi d e d b el o w. 
I6T-MC-AMBE Clinical Pharmacology Protocol Page 2
LY3074828Table of Contents
A Safety , Tolerability , and Pharmacokinetic Study  of 
Injections of LY3074828 Solution Using Investigational 
1-mLPre-filled Sy ringes and Investigational 
1-mLAutoinjector in Healthy  Subjects
Section Page
Protocol  I6T-MC-AMBE A Safety, Tolerabilit y, and Pharmacokinet ic 
Study  of Inject ions of LY3074828 Solut ion Using Invest igational 
1-mL Pre-filled Syringes and Invest igational 1 -mLAutoinjector in 
Healthy Subjects ................................................................................................................. 1
Table of Contents ........................................................................................................................ 2
1. Protocol  Synopsi s................................................................................................................ 7
2. Schedule of Act ivities....................................................................................................... 10
3. Introduction ...................................................................................................................... 14
3.1. Study  Rati onale ............................................................................................................ 14
3.2. Background .................................................................................................................. 14
3.3. Benefit/Risk Assessment .............................................................................................. 16
4. Object ives and Endpo ints.................................................................................................. 17
5. Study  Design ..................................................................................................................... 18
5.1. Overall Design ............................................................................................................. 18
5.2. Number of Participants ................................................................................................
.19
5.3. End of Study  Definit ion............................................................................................... 19
5.4. Scientific Rationale for Study  Design ........................................................................... 19
5.5. Justification for Dose ................................................................................................... 19
6. Study  Popul ation............................................................................................................... 20
6.1. Inclusio n Cri teria.......................................................................................................... 20
6.2. Exclusio n Cri teria........................................................................................................ 22
6.3. Lifest yle and/or Dietary Requirements ......................................................................... 24
6.3.1. Meals and Dietary  Restri ctions............................................................................. 24
6.3.2. Caffeine, Alcoho l, and Tobacco ........................................................................... 24
6.3.3. Activity................................................................................................................ 24
6.3.4. Bloodand Plasma Donation ................................................................................. 24
6.4. Screen Failures ............................................................................................................. 24
7. Dosing Regimens .............................................................................................................. 25
7.1. Dosin g Regimens Administered ................................................................................... 25
7.1.1. Packaging and Labeling ....................................................................................... 26
I6T-MC-AMBE Clinical Pharmacology Protocol Page 3
LY30748287.2. Method of Treatment Assignment ................................................................................ 26
7.2.1. Selection and Timing o f Doses ............................................................................. 26
7.3. Blinding ....................................................................................................................... 26
7.4. Dose Modificat ion........................................................................................................ 26
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... 27
7.6. Treatment Compliance .................................................................................................27
7.7. Concomitant Therapy ................................................................................................... 27
7.8. Treatment after the End of the Study ............................................................................ 27
8. Discontinuati on Cri teria .................................................................................................... 28
8.1. Discontinuati on from Study  Treatm ent......................................................................... 28
8.1.1. Discontinuati on of  Inadvertent ly Enrolled Subjects .............................................. 28
8.2. Discontinuati on from the Study .................................................................................... 28
8.3. Subjects Lost to Follow -up........................................................................................... 28
9. Study  Assessments and Procedures ................................................................................... 29
9.1. Efficacy Assessments ................................................................................................... 29
9.
2. Adverse Events ............................................................................................................ 29
9.2.1. Serious Adverse Events ........................................................................................ 30
9.2.1.1. Adverse Device Effects .................................................................................. 31
9.2.1.2. Adverse Events of Special Interest .................................................................. 31
9.2.1.3. Suspected Unexpected Serious Adverse React ions.......................................... 31
9.2.2. Com plaint Handling ............................................................................................. 31
9.3. Treatment of Overdose .................................................................................................32
9.4. Safety........................................................................................................................... 32
9.4.1. Laboratory  Tests .................................................................................................. 32
9.4.2. Vital Signs ........................................................................................................... 32
9.4.3. Electrocardi ogram s.............................................................................................. 33
9.4.4. Other Tests ........................................................................................................... 33
9.4.4.1. Tuberculosis Test ing....................................................................................... 33
9.4.4.2. Inject ion Duration Assessments ...................................................................... 33
9.4.4.3. Inject ion-Site Assessments ............................................................................. 34
9.4.4.4. Bleeding Assessment ...................................................................................... 34
9.4.4.5. Inject ion-Site Pain .......................................................................................... 34
9.4.5. Safety Moni toring ................................................................................................ 34
9.4.5.1. Hepati c Safet y................................................................................................ 35
9.4.5.2. Moni toring of Hy persensi tivity Reacti ons....................................................... 35
9.5. Pharmacokinet ics......................................................................................................... 36
9.5.1. Bioanalysis ........................................................................................................... 36
9.6. Pharmacodynamics ...................................................................................................... 36
I6T-MC-AMBE Clinical Pharmacology Protocol Page 4
LY30748289.6.1. Immunogenicit y Assessments .............................................................................. 36
9.7. Genet ics....................................................................................................................... 37
9.8. Biomarkers ................................................................................................................... 37
9.9. Heal th Economics ........................................................................................................ 37
10. Statistical Considerations and Data Analysis ..................................................................... 38
10.1. Sample Si ze Determinat ion.......................................................................................... 38
10.2. Popul ations for Analyses .............................................................................................. 38
10.2.1. Study  Parti cipant Disposit ion............................................................................... 38
10.2.2. Study  Parti cipant Characterist ics.......................................................................... 38
10.3. Statistical Analyses ...................................................................................................... 38
10.3.1. Safety Analyses .................................................................................................... 39
10.3.1.1. Clinical Evaluation of Safet y.......................................................................... 39
10.3.1.2. Statistical Evaluat ion of Safet y....................................................................... 39
10.3.1.2.1. Inject ion-Site Pain .................................................................................... 39
10.3.1.2.2. Durati on of  Inject ion................................................................................. 39
10.3.1.2.3. Inject ion-Site Assessments ........................................................................ 40
10.3.1.2.4. Statistical Evaluat ion of Other Safet y Param eters ...................................... 40
10.3.2. Pharmacokinet ic Analyses .................................................................................... 40
10.3.2.1. Pharmacokinet ic Parameter Estimat ion........................................................... 40
10.3.2.2. Pharmacokinet ic Statistical Inference ............................................................. 40
10.3.3. Pharmacodynamic Analyses ................................................................................. 40
10.3.4. Pharmacokinet ic/Pharmacodynamic Analyses ...................................................... 40
10.3.5. Evaluat ion of Immunogenicit y............................................................................. 41
10.3.6. Data Review During the Study ............................................................................. 41
10.3.7. Interim Analyses .................................................................................................. 41
11. References ........................................................................................................................ 42
I6T-MC-AMBE Clinical Pharmacology Protocol Page 5
LY3074828List of Tables
Table Page
Table AMBE.1. Object ives and Endpo ints....................................................................... 17
Table AMBE.2. Dosing Regimens Administered ............................................................. 25
I6T-MC-AMBE Clinical Pharmacology Protocol Page 6
LY3074828List of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions................................................................ 43
Appendix 2. Clinical Laboratory  Tests ........................................................................ 47
Appendix 3. Study  Governance, Regulatory  and Ethi cal Considerati ons..................... 48
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y............ 51
Appendix 5. Blood Sam pling Summary ...................................................................... 52
I6T-MC-AMBE Clinical Pharmacology Protocol Page 7
LY30748281.Protocol Synopsis
Title of Study:
A Safety, Tolerability, and Pharmacokinetic Study of Injections of LY3074828 Solution Using Investigational 
1-mL Pre -filled Syringes and Investigational 1-mL Autoinjector in Healthy Subjects
Rationale: 
Study I6T-MC -AMBE (AMBE ) will assess the pharmacokinetics (PK), safety and tolerability of, and pain 
associated with ,a 125-mgsubcutaneous (SC) dose of LY3074828 solution formulation administered using a n 
investigational manual 1
-mL pre-filled syringe (PFS) or an investigational 1-mL autoinjector (AI).  Both methods of 
administration will be evaluated at 3 different injection sites (arm, thigh, and abdomen) in order to expand the 
options for administration in patient use .  The study wi ll provide data to bridge PFS administration of LY3074828, 
with the investigational AI device planned for use in subsequent studies and patient use.
Objective s/Endpoints:
Objectives Endpoints
Primary
To evaluate the PK after SC administration of 
125-mg doses of LY3074828 solution 
formulation using a 1
-mL PFS and a 1-mLAI 
inject orin healthy subjects.
To assess pain associated with LY3074828 
PFS and AI SC administrations in healthy 
subjects at 3 different injection sites (arm, 
thigh, and abdomen) .The primary PK endpoints will be the C max, 
AUC(0 -tlast), and AUC(0-∞) of LY3074828.
VAS pain score.
Secondary
To assess the safety and tolerability of 
LY3074828 in healthy subjects.Incidence of TEAEs.
Abbreviations:  AI = autoinjector; AUC(0 -∞) = area under the concentration versus time curve from time zero to 
infinity ; AUC(0 -tlast) = area under the concentration versus time curve from time zero to time t, where t is the 
last sample with a measurable concentration; C max= maximum observed drug concentra tion; PFS = pre -filled 
syringe; PK = pharmacokinetic; SC = subcutaneous; TEAE =treatment -emergent adverse event; VAS = visual 
analog scale.
I6T-MC-AMBE Clinical Pharmacology Protocol Page 8
LY3074828Summary of Study Design:
Study I6T-MC -AMBE (AMBE ) is a single -center, randomized, parallel -arm, open -label, Phase 1 single -dose study 
of LY3074828 solution formulation in healthy subjects.  Pharmacokinetics, safety and tolerability of, and pain 
associated with, 125-mgSC doses administered using a PFS or an investigational AI at 3different injection sites 
will be evaluated.
Subjects will be randomized to a 1-mL PFS administ ration to the arm, thigh, or abdomen or a 1-mLAI
administ ration to the
arm, thigh, or abdomen.  Subjects will report to the clinical research unit (CRU) on Day -1 and 
will remain at the CRU unti l the scheduled procedures have been completed on Day 2.  Study drug will be 
administered by investigative site staff by SC injection per the randomization scheme in the morning of Day 1 after 
an overnight fast.  Subjects will be followed for 12 weeks foll owing dose administration.
Safety and tolerability will be assessed by clinical laboratory tests, vital sign measurements, 12 -lead 
electrocardiograms, recording of adverse events and product complaints, physical examinations/medical 
assessments, immunogeni city, and injection -site assessments.  Pain assessments will be made using aninjection -site 
pain visual analog scale (VAS).
Dosing Regimen Arms and Duration for an Individual Subject :  
Subjects will receive a 125-mgSC dose of LY3074828 and will be randomized to 1 of 6 dosing regimen arms:
Test 1:  1-mL AI injector containing 125 mg LY3074828 solution to be administered in the arm
Test 2:  1-mL AI injector containing 125 mg LY3074828 solution to be administered in the thigh
Test 3:  1-mL AI injector containing 125 mg LY3074828 solution to be administered in the a bdomen
Reference 1:  1-mL PFS containing 125 mg LY3074828 solution to be administered in the arm
Reference 2:  1-mL PFS containing 125 mg LY3074828 solution to be administered in the thigh
Reference 3:  1-mL PFS containing 125 mg LY3074828 solution to be administered in the a bdomen
Total duration of the study for each subject will be approximately 16 weeks (screening period ≤28 days, reside ntial 
period of 2 days, and outpatient follow -up period of 12 weeks).
Number o f Subjects :
A total of approximately 66subjects who fulfill the eligibility criteria will be randomized to 1 of 6 dosing regimen 
arms , with 11subjects randomized to each arm to ensure completion of 10subjects in each (60 subjects completed 
in total) .  A subject’s study participation is considered as complete if he/she receives the study drug as per the 
protocol requirements and completes all activities up to and including at least Day 57.  A maximum of 2 subjects per 
arm may be replaced if multiple subjects do not complete the study.
Statistical Analysis:
The area under the concentration versus time curve (AUC) from time zero to infinity (AUC[0 -∞]), AUC from time 
zero to time t, where t is the last sample with a measurable concentration (AUC[0 -tlast]), and maximum observed 
drug concentration (C max) will be log -transformed and analyzed using a linear fixed-effects model.  The model will 
include device and injection location as fixed effect s.  The dosing regimen differences between AIand PFS 
I6T-MC-AMBE Clinical Pharmacology Protocol Page 9
LY3074828administration swill be back -transformed to present the ratios of geometric least squares (LS) means and the 
corresponding 90% confidence interval (CI).
The time to C max(tmax) of LY3074828 b etween AI an d PFS administration swill be analyzed using a Wilcoxon rank 
sum test.  Estimates of the median difference, 90% CIs, and p -values from the Wilcoxon rank sum test will be 
calculated.
Additional PK analyses may be conducted if deemed appropriate.
Alinear fixed -effects model will be used to analyze the post -injection pain VAS score s.  The model will include 
device and injection location as fixed effect s.  The LS means and differences in LS means will be presented along 
with the corresponding 90% CI. 
Safety  parameters will be listed and summarized using standard descriptive statistics , as appropriate .
I6T-MC-AMBE Clinical Pharmacology Protocol Page 10
LY30748282.Schedule of A ctivities
I6T-MC-AMBE Clinical Pharmacology Protocol Page 11
LY3074828Study Schedule Protocol I6T-MC-AMBE
Screening Days Comments
Procedure ≤28 days -1 1 24
±1d8
±1d11
±1d15
±2d22
±2d29
±2d43
±2d57
±3d71
±3d85/ED
±3d
Informed consent X
Review/confirm 
inclusion/exclusion 
criteriaX X Any time prior to dosing.
Subject admission to 
CRUX
Subject discharge 
from CRUX
Outpatient visit X X X X X X X X X X X
Randomization XSubjects randomized to 1 of 6dosing regimen
arms.
LY3074828 injection X Doses administered by investigative site staff.
Stopwatch recording XStopwatch is the source for injection duration
capture for PFS and AI .
Medical history X
Weight, height, and 
BMIX
Vital signs:  blood 
pressure, pulse rate, 
temperature (hour)X X 0, 6 24 X X X X X X X XTimes with respect to start of dosing.  Single 
ECGs to be collected.  Zero -hour collection 
within 30 minutes before dosing.  Time 
allowance for 6- and 24 -hour time points:  ±30 
and ±90 minutes, respectively.  For vital sign 
assessments, temperature need only be 
included at predose and when clinically 
indicated.12-lead ECG (hour) X 0 24 X
Physical examination/ 
medical assessmentX X X X XFull physical examination/medical assessment 
at screening.  Symptom -directed phy sical 
examination/medical assessment at all other 
time points, and as deemed necessary by the 
investigator.
I6T-MC-AMBE Clinical Pharmacology Protocol Page 12
LY3074828Screening Days Comments
Procedure ≤28 days -1 1 24
±1d8
±1d11
±1d15
±2d22
±2d29
±2d43
±2d57
±3d71
±3d85/ED
±3d
AE review X X X X X X X X X X X X X XAE only after signing ICF.  Product complaints 
and device -related AEs collected as 
appropriate.
QuantiFERON ®-TB 
Gold test X
Serology X See Appendix 2 for test details.
Ethanol test and urine 
drug screenX XMay be repeated at the discretion of the 
investigator.  E thanol test may be measured in 
blood, urine ,or expired air .  See Appendix 2
for test details.
FSH/serum 
pregnancy testX X X X XSerum pregnancy tests for all female subjects
at screening.  For all w omen who are 
considered to be p eri-menopausal, FSH should 
be drawn at screening to confirm 
postmenopausal status as defined in inclusio n 
criterion [1b ].  Women with confirmed 
postmenopausal status at screening are 
exempted from further pregnancy tests during 
the study .  See Appendix 2 for test details.
Clinical chemistry, 
hematology, and 
urinaly sisX X X X X X See Appendix 2 for test details.
Creatine 
phosphokinaseX X X
Injection -site 
assessment for 
erythema, induration, 
pruritus, and edema
(hour)0, 0.25 X X XTimes with respect to start of dosing.  
Zero-hour assessments within 1minute 
following injection.  Time allowance for 
0.25-hour assessment is ±5minutes.  
Additional assessments performed if deemed 
necessary by the investigator.
Injection -site 
bleeding assessment 
(hour)0Time with respect to start of dosing.  
Zero-hour assessment within 1 minute 
following injection.  
I6T-MC-AMBE Clinical Pharmacology Protocol Page 13
LY3074828Screening Days Comments
Procedure ≤28 days -1 1 24
±1d8
±1d11
±1d15
±2d22
±2d29
±2d43
±2d57
±3d71
±3d85/ED
±3d
Pain assessment 
(VAS) (minutes)1, 5, 15 , 
30, 60, 
120Time with respect to start of dosing.  Time
points are minutes post -injection as follows: 
within 1 minute of the end of injection, 5 
(±1.5), 15(±2), 30(±2), 60(±5), 120(±5)
minutes
LY3074828 
pharmacokinetic 
sampling (hour)0, 2, 6 24 X X X X X X X X X XTimes with respect to start of dosing.  
Zero-hour collection immediately (within 
15minutes) before dosing.  Time allowance 
for 2 -, 6-, and 24 -hour time points:  ±15, ±30, 
and ±90 m inutes, respectively.
For the 2 -hour postdose timepoint, VAS pain 
assessment should be conducted prior to PK 
sample collection.
Immunogenicity 
samplePredose X X X XLY3074828 antibody sample.   In the event of 
an AE that could be immunologically 
mediated , additional samples may be taken 
(See Section 9.6.1 ).  Predose sample may be 
collected within 2 hours prior to planned 
dosing.
Pharmacogenetics 
sampleX
Abbreviations:   AE=adverse event; AI = autoinjector; BMI = body mass index; CRU = clinical research unit; d =day; ECG =electrocardiogram; ED =early 
discontinuation; FSH = follicle -stimulating hormone; ICF =informed consent form ;PFS = pre -filled syringe; TB =tuberculosis; VAS = visual analog scale.
Siteshould schedule activities as appropriate. For the 2 -hour postdose timepoint, VAS pain assessment should be conducted prior to pharmacokinetic sample 
collection. In other cases where several study procedures are scheduled at the same time, follow this o rder of priority for procedures:  pharmacokinetic 
samples, clinical laboratory tests, immunogenicity sample, stored sample, ECG, vital signs, pain assessment, injection -site assessment, such that 
pharmacokinetic sample collection occurs as close to the nom inal collection time as possible.  
I6T-MC-AMBE Clinical Pharmacology Protocol Page 14
LY30748283.Introduction
3.1. Study Rationale
Study  I6T-MC-AMBE (AMBE) will assess the pharmacokinet ics (PK), safet y and tol erabilit y of, 
and pain associated with, a 125 -mg subcutaneous (SC) dose of LY3074828 so lution formulation 
administered using an invest igational manual 1-mL pre-filled syringe (PFS) or an invest igational 
1-mL autoinjector (AI).  Both devices will be evaluated at 3 different injection sites (arm, thigh, 
and abdo men) in order to expand the options for administration in patient use.  The study  will 
provi de data to bri dge PFS administration of LY3074828, with the invest igational AI device 
planned for use in subsequent studies and pat ient use.
3.2. Background
LY3074828 is a humanized immunoglobulin G4 -variant monoclonal ant ibody  that i s directed 
against the p19 subunit of interleukin (IL)-23 and does not bind IL-12.  LY3074828 is being 
developed for the treatment of autoimmune diseases in which the IL -23 pathway  is thought to 
have a significant pathogenic role.   
Neutralizat ion of IL-23 with an anti -mouse IL -23 surrogate 
antibody  (directed against the p19 subunit) significant ly reduced the development of arthrit is and 
inhibited ileal inflammat ion in a mouse model o f spondyloarthropathy  with bowel  inflammat ion 
(Ruutu et al. 2012).  Addit ionally , neutralizat ion of IL -23 significant ly reduced the disease score 
in the relapsing -remitt ing experimental autoimmune encephalo myelit is (m ultiple sclerosis -like) 
model in mice.  Anti -IL-23 antibody  also dem onstrated som e effic acy in preclinical  arthri tis 
models, depending on the timing of intervent ion (Cornelissen et al. 2013).  
Psori asis is one of the most commo n immune -mediated chronic inflammatory  skin diseases, 
affect ing about 2% to 3% of the world's populat ion (Nestle et al. 2009; Perera et al. 2012).  A 
typical organ -specific T -cell-driven inflammatory  disease, psoriasis
,had been considered a 
Thelper (Th) 1- type skin disease for decades unt il a new Th population, Th17, was ident ified 
(Lew et al . 2004; Steinman 2007; Wea ver et al. 2007).  However, substant ial clinical and basic 
research observat ions now suggest that the IL -23/Th17 axis is essent ial in the pathogenesis o f 
psori asis (Di  Cesare et al . 2009).  Treatment of psoriasis wit h bio logic therapy , parti cularly wi th 
those agents targeting the IL -23/Th17 axis, has demo nstrated clinical activit y in pat ients with 
psori asis (Crow 2012).
As of the Invest igator’s Brochure (IB) cutoff date (02 February 2018 for Phase 1 studi es), there 
have been approximately 819 participants i n studi es of  LY3074828.  These include 245 patients 
with psoriasis, 248 patients wi th ulcerat ive co litis, 85 patients wi th Crohn’s disease, and 
241healt hy subjects who were exposed to either placebo or LY3074828 at single doses ranging 
from 5 to 1200 mg a nd m ultiple doses up to a maximum o f 1000 mg int ravenous (IV) and 
300mg SC.
Data from the clinical pharmaco logy devel opment program  are available for 2completed 
Phase 1 studi es(Studi esI6T-MC-AMA A [AMA A]and I6T-MC-AMA E [AMA E])and 
I6T-MC-AMBE Clinical Pharmacology Protocol Page 15
LY30748284ongoing Phase 1 studi es(Studi esI6T-JE-AMAD [AMAD ], I6T -MC-AMAL [AMAL ],
I9O-MC-AABA [AABA ],andI6T-MC-AMA Q [AMA Q]).
No deaths, serious adverse events (SAEs), or discont inuat ions due to an adverse event (AE) have 
been reported in any o f the Phase 1 studi es.
In the com pleted Study AMAA, a total of 82 treatment -emergent AEs (TEAEs) were reported by  
37subjects.  The most commo nly reported TEAEs in this study  were nasopharyngit is and 
headache.  There were no drug- related TEAEs of National Cancer Inst itute Commo n 
Termino logy Criteria for Adverse Events Grade 2 or higher reported in Study AMAA.  
In the com pleted Study  AMAE, the incidence of TEAEs was similar between the 125 m g
LY3074828 lyophilized formulat ion and the 125 mg LY3074828 PFS so lution formulation, wi th 
a notably  higher number of TEAEs reported by  healthy subjects who received 500 mg 
LY3074828 solut ion formulation.  The most commo n TEAEs related to study  treatm ent were 
events occurring at the site of injection, including inject ion-site reacti on (ISR)and injection -site 
hemorrhage.  Across all formulat ions, the m ajority of TEAEs reported during the study  were 
mild, wi th only  1TEAE that was m oderate in severi ty but not related to study  drug.  
There were no obvious trends in the pattern of AEs across studies apart from ISRs .  Injection-site 
pain, of short duration (usually hours), has been reported in both the completed and ongoing 
clinical pharmaco logy studi es.  Preliminary  data from  Studi esAMAE and AMAL showed that 
most ISRs were mild or moderate in severit y, with severe inject ion-site pain reported in 2% of 
ISRs in the 125-mgSCsolutiontestformulation group.
Immunogenicit y evaluat ions were performed in Study  AMAA. Blood sam ples to evaluat e 
anti
-drug ant ibody (ADA ) were collected at baseline and approximately 22, 43, and 85 day s 
postdose. Anti- drug ant ibody data were available for 45 subjects: 38 who received LY3074828 
and 7 who received placebo. All subjects who received placebo were AD A negative at baseline 
andpost-baseline. Only 1 subject who received LY3074828 was posit ive at baseline. Thirty-one
subjects who received LY3074828 (81.6%) were negative at all post- baseline t ime points
evaluated. Seven subjects who received LY3074828 had a post -baseline posit ive titer; however,
only 3 of those subjects (7.9% of LY3074828 -treated individuals) developed treatm ent-emergent 
ADA (TE- ADA). Treatment -emergent posi tive ADA was defined as ADA that devel oped 
following study  drug administrati on with an increase to ≥1:20 titer (2 dilut ions/4-fold increase) 
after a negative baseline result OR preexist ing ADA (ADA posit iveat baseline) that was 
increased at least 2 dilut ions/4-fold over baseline following study  drug administration. None of 
these ca ses of TE -ADA were associated with treatment -emergent adverse events (TEAEs) or 
changes in the clearance of LY3074828 in this study .
Study  AMAE evaluated the relat ive bioavailabilit y of LY3074828 so lution formulation in PFSs 
and a lyophilized form ulation.  A total of 8 subjects (14.8%) we re ADA positive at predose 
(pre-existing react ivity); none of the pre -exist ing reactivit y confirmed as posit ive for neutralizing 
antibodies. The incidence of TEADAs was similar across formulat ions,with 7 subjects (38.9%) 
administered 250 mg LY3074828 ly ophilized formul ation, 6 subjects (33.3%) administered 
250mg LY3074828 PFS solut ion formulation, and 7 subjects (38.9%) administered 500 mg 
I6T-MC-AMBE Clinical Pharmacology Protocol Page 16
LY3074828LY3074828 PFS formulat ion testing positive for TEADAs. Most TEADAs were treatment -
induced (33.3% of subjects), with only 2 subjects having treatment -boosted TEADAs. Only 
1subject had an ADA t iter >1:1000 and there was no obvious trend towards a particular 
formulation having higher titers.
One subject had a TEA DA ti ter greater than 1:1000 and met the protocol -defined requirement to 
have fo llow-up samples tested until t iters were trending back to baseline. Multiple attem pts were 
made to contact this subject for fo llow-up visit s, but there was no response and the subject was 
considered lost to fo llow-up. The subject’s last recorded titer was 1:2560 at the final study  visit
on Day  85.
3.3. Benefit/Risk Assessment
Based on LY3074828 nonclinical and preliminary clinical data, there are no anticipated risks 
requi ring m onitoring bey ond those for a ty pical  humanized m onoclonal antibody  in human 
studi es.  As wi th other immunom odulatory  therapies, LY3074828 may  increase t he risk of 
developing an infect ion or m ay exacerbate an existing serious infect ion.  These may  include 
opportunist ic infect ions and react ivation of latent infect ions, such as tuberculosis (TB) and 
hepat itis B.  Subjects will therefore be screened for hepat itis B/C, human immunodeficiency 
virus (HIV), and TB.  Immuno modulatory  therapi es may increase the risk of malignancies; 
however, due to only single doses of LY3074828 being administered in this study , it is not 
considered necessary  to m onitor for such eff ects.  
Based on available data fro m Studi esAMAA and AMAD, TE-ADAs have been observed in 2 of 
the 11 healthy subjects that received SC doses of LY3074828; however, titers were ≤1:160.  In 
the 33 patients with psoriasis who received single IV doses of LY30 74828, TE -ADAs were 
detected in 3 subjects (Study AMAA).
No clinically  significant safet y or tol erabilit y concerns have been identified in pat ients or healthy 
subjects to date for LY3074828 up to the highest doses given (single 2 400-mg IV doses and 
2400- mgSC doses).  
Healthy subjects are not expected to derive any benefit from participating in studies wit h 
administration of LY3074828.  
As thi s study  will use PFS and AIs, device -based risks will be evaluated.  Possible device -based 
risks include local eff ects such a s pain at the injectio n sites fro m either the needle or the solut ion 
entry  into the SC ti ssue, swelling, ery thema, bleeding, and bruising.  These risks are mit igated by  
training o f investigative site staff on proper inject ion techniques.  Sy stem ic effects may include 
sweat ing, feeling faint, or fever, as a sign of infect ion.  
More informat ion about the known and expected benefits, risks, SAEs, and reasonably 
anticipated AEs of LY3074828 are found in the compound IB,and risks as well as reasonably 
anticipated adverse device effects of the AI are found in the device IB .
I6T-MC-AMBE Clinical Pharmacology Protocol Page 17
LY30748284.Objectives and Endpoints
Table AMBE .1shows the object ives and endpo ints of the study .
Table AMBE .1. Objectives and Endpoints
Objectives Endpoints
Primary
To evaluate the PK after SC administration of 
125-mg doses of LY3074828 solution 
formulation using a 1 -mL PFS and a 1-mL AI 
injector in healthy subjects.
 To assess pain associated with LY3074828 
PFS and AI SC administrations in healthy 
subjects at 3 different injection sites (arm, 
thigh, and abdomen) .The primary PK endpoints will be the C max, 
AUC(0 -tlast), and AUC(0
-∞) of LY3074828.
VAS pain score.
Second ary
To assess the safety and tolerability of 
LY3074828 in healthy subjects.Incidence of TEAEs.
Abbreviations:  AI = autoinjector; AUC(0 -∞) = area under the concentration versus time curve from time zero to 
infinity ; AUC(0 -tlast) = area under the concentration versus time curve from time zero to time t, where t is the 
last sample with a measurable concentration; C max= maximum observed drug conc entration; PFS = pre -filled 
syringe; PK = pharmacokinetic; SC = subcutaneous; TEAE =treatment -emergent adverse event; VAS = visual 
analog scale.
I6T-MC-AMBE Clinical Pharmacology Protocol Page 18
LY30748285.Study  Design
5.1. OverallDesign
Study  I6T-MC-AMBE (AMBE ) is a single -center, randomized, parallel -arm, open -label, Phase 1 
single- dose study  of LY3074828 so lution formulation in healt hy subjects.  Pharmacokinet ics, 
safet y and tolerabilit y of, and pain associated with , 125- mgSC doses administered using a PFS 
or AI at 3 different inject ion sites will be eval uated.
Screening Period ( ≤28 days):   
Subjects will be evaluated for study eligibilit y ≤28 days pri or to 
enrollment.
Residential Period (2 days):   A total of approximately 66subjects who fulfill the eligibilit y 
criteria will be rando mized to 1 of 6 dosing regimen arms, wi th 11subjects rando mized to each 
arm to ensure com pletion of  10subjects in each:
Test 1:  1 -mL AI injector containing 125 mg LY3074828 solut ion to be administered in 
the arm
Test 2:  1 -mL AI injector containing 125 mg LY3074828 solut ion to be administered in 
the thigh
Test 3:  1 -mL AI injector containing 125 mg LY3074828 solut ion to be administered in 
the abdo men
Reference 1:  1 -mL PFS containing 125 mg LY3074828 solut ion to be administered in 
the arm
Reference 2:  1 -mL PFS containing 125 mg LY3074828 solut ion to be administered in 
the thigh
Reference 3:  1 -mL PFS containing 125 mg LY3074828 solut ion to be administered in 
the abdo men
Subjects will report to the clinical research unit (CRU) on Day  -1 and will remain at the CRU 
until the sche duled procedures have been co mpleted on D ay 2.  Study  drug will be administered 
by invest igative site staff by SC inject ion per the rando mizat ion scheme in the morning o f Day 1 
after an overnight fast.  
Safety and tol erabilit y will  be assess ed by  clinical laboratory  tests, vi tal sign measurements, 
12-lead electrocardiograms ( ECGs ), recording of AEs and product complaints (PCs) , physical 
examinat ions/medical assessments, immunogenicity, and inject ion-site assessments.  Pain 
assessments will be made using aninject ion-site pain visual analog scale ( VAS ).
Outpatient Follow -up Period (12 weeks):   The follow -up peri od will include outpatient visits 
for a total  of 12 weeks (Days 4, 8, 11, 15, 22, 29, 43, 57, 71, and 85 )following dose 
administration on Day  1 to a ssess the PK, safet y and tol erabili ty of, and pain associated with 
LY3074828 PFS and AI administrations .  Assessment of pain at the Follow -up visit s does not 
include VAS score.
I6T-MC-AMBE Clinical Pharmacology Protocol Page 19
LY30748285.2. Number of Participants
A total o f approximately  66subjects who fulfill the eli gibilit y criteria will be rando mized to 1 of 
6 dosing regimen arms, with 1 1subjects rando mized to each arm to ensure complet ion of
10subjects in each.  A subject’s study  parti cipat ion is considered as co mplete if he/she receives 
the study  drug as per the protocol requirements and completes all activit ies up to and including at 
least Day  57.  A m aximum  of 2subjects per arm may  be repl aced if mult iple subjects do not 
complete the study .
5.3. End of Study Definition
End of the study is the date of the last visit or last scheduled procedure shown in the Schedule o f 
Activities(Secti on 2) for the last subject .
5.4. Scientific Rationa le for Study Design
Conducting the study  in healt hy subjects mit igates the potenti al confounding effects of the 
disease state and concomitant medications in pat ients.  A populat ion of h ealthy subjects is
frequently used in the assessment of bioavailabilit yof both small and large mo lecules.
Single doses of LY3074828 and the PK sampling time points have been selected to generate PK 
profiles sufficient to fulfill the study  object ives.  This study  is notblinded due to the physical 
difference in devices being evaluated .  Subj ects and si te staff will be aware of the administration 
route and treatment.
A parallel -group desi gn was chosen because a crossover design is impract ical for com pounds 
that have long half -lives, such as mo nocl
onal antibodies.  Addit ionally ,a crossover study  design 
could confound PK data if subjects develop neutralizing ADAs.
Monoclonal  antibody  therapy  has been associ ated wi th hypersensit ivity react ions, including 
ISRs.  Follow -up details on ISRs will be co llected by the investigative site regarding the severit y, 
durati on, ty pe, and timing of the start of the event in relat ion to the start of study  drug 
administration in order to further characterize these events.
Methods of administration will be evaluated at 3 different inject ion sites (arm, thigh, and 
abdo men) in order to expand the options for administration in pat ient use.  
5.5. Justification for Dose
The doses for this study  are based on the vo lume of solut ion that can be delivered by the PFS or 
AI (1 mL) and the so lubility of LY3074828 (125 mg/mL), result ing in a dose of 125 m g
LY3074828.  
Intravenous d oses up to 2 400mg and SC doses up to 2400 mg were found to be well tolerated in 
healt hy subjects in the single -dose Stud iesAMAD and AABA .  Subcutaneo us bioavailabilit y 
was approximately 40% in Study AMAA.   
In additio n, 125 mg is one of the doses that are being 
evaluated in the Phase 3 development program .
I6T-MC-AMBE Clinical Pharmacology Protocol Page 20
LY30748286.Study  Population
Eligibilit y of subjects for study  enrollment will be based on the results of medi cal history , 
physical examinat ion, vital signs, clinical laboratory tests, and ECG.  
The nature of any condit ions present at the time of the physical examinat ion and any preexist ing 
condi tions will  be docum ented.
Screening will occur up to 28 day s prior to enrollment.  Subjects who are not enrolled within 
28days of screening may  be subjected to an addit ional medical assessment and/or clinical 
measurements to confirm their eligibilit y.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, al so known as 
protocol  waivers or exempt ions, are not permitted.
6.1. Inclusion Criteria
Subjects are eligible for inclusio n in the study  only if they  meet all  of the f ollowing criteria at 
screening and/or enr ollment:
[1] are overtly healt hy male o r female subjects, as determined by medical 
history  and physical examinat ion
[1a] male subjects:
no male contraception required except in compliance with specific local 
government study  requi rement
[1b] female subjects:
All female subjects must test negati ve for pregnancy  prior to ini tiation of treatm ent 
as indicated by  a negat ive serum pregnancy test at the screening visit . Women of 
childbearing potential must also have a negat iveserum  pregnancy test within 
24hours prior to initial exposure .  Wo men not of childbearing potential due to 
postm enopausal status must have follicle -stimulat ing hormone >40 m IU/mL at the 
screening visit
Women of childbearing potential who are abstinent (if this is co mplete abst inence, 
as thei r pref erred and usual lifest yle) or in a same -sex rel ationship (as part of their 
preferred and usual lifest yle) must agree to either remain abst inent or stay in a 
same -sex rel ationship wi thout sexual relat ionships with males.  Periodic abst inence 
(eg, calendar, ovulat ion, symptothermal, post -ovulation methods), declarat ion of 
abstinence just for the duration of a trial, and wit hdrawal  are not acceptable 
methods of contraception
Otherwi se, women of childbearing potential part icipating must agree to use one 
highly  effect ive method (less than 1% f ailure rate) of contraception, or a 
combinat ion of 2 effect ive methods of contraception (for 12 weeks fo llowing 
dosing wit h the study  drug)
I6T-MC-AMBE Clinical Pharmacology Protocol Page 21
LY3074828oEither one hi ghly effect ive method of contraception (such as combinat ion 
oral contraceptives, implanted contracepti ves, or intrauterine device) or a 
combinat ion of 2 effect ive methods of contraception (such as male or 
female condo ms with spermicide, diaphragms wit h spermicide, or cervical 
sponges) will be used.  The subject may  choose to use a doubl e-barrier
method of contraception.  Barrier protection methods without concomitant 
use of a spermicide are not reliable or acceptable method s.  Thus, each 
barrier m ethod m ust include use of a spermicide.  It should be noted that the 
use of male and female condo ms as a doubl e-barrier method is not 
considered acceptable due to the high failure rate when these methods are 
combined
Women not of childbearing potential may participate and include those who are: 
oinfertile due to surgical sterilizat ion (hysterectomy, bilat eral oophorectomy, 
or tubal ligation) or congenital anomaly such as Müllerian agenesis; or 
opostm enopausal –defined as eit her:
A wo man at l east 50 years of age with an intact uterus, not on 
horm one therapy , who has had either:
cessat ion of menses for at l east 1 y ear; or 
at least 6 m onths of spontaneous amenorrhea with a 
follicle -stimulat ing horm one >40 m IU/mL ; or 
A wo man 55 years of age or older not on horm one therapy , who has 
had at least 6 months of spontaneous amenorrhea; or 
A wo man at l east 55 years of age wi th a diagnosi s of menopause 
prior to starting hormone -replacement therapy
[2] are between 18 and 65 y ears of age, inclusive, at time of screening
[3] have a body  mass index (BMI) of 18.0 to 32.0 kg/m 2, inclusive, at time of 
screening
[4] have cli nical  laboratory  test resul ts wi thin norm al reference range sfor the 
investigat ive site, or results with acceptable deviat ions that are judged to be 
not clinically significant by  the invest igator
[5] have venous access sufficient to allow for blood samplin g as per the 
protocol
[6] are reliable and willing to make themselves available for the duration of the 
study  and are willing to follow study  procedures
[7] are able and willing to give signed informed consent
I6T-MC-AMBE Clinical Pharmacology Protocol Page 22
LY30748286.2. Exclusion Criteria
Subjects will be excluded f rom study  enro llment if they meet any o f the following cri teria at 
screening and/or enrollment:
[8] are invest igative site personnel direct ly affiliated with this study  and thei r 
imme diate families.  Immediate family  is defined as a spouse, biological or 
legal guardian, child, or sibling
[9] are Lilly  empl oyees or em ployees o f Covance
[10] are currently enrolled in a clinical study  involving an invest igational 
product (IP) or any  other ty pe of  medical  research judged not to be 
scientifically or medically co mpatible wit h this study
[11] have participated in a clinical trial invo lving an IP within 30 days or 
5half-lives (whichever is lo nger) prior to screening.  If the clinical trial 
involved treatment with bio logic agents (such as monoclonal ant ibodies, 
including m arketed drugs), at least 3 months or 5 half -lives (whichever is 
longer) should have elapsed prior to Day  1
[12] have previously completed or withdrawn fro m this study  or any  other study  
investigat ing LY3074828, and have previously received the IP
[13] have ever received ant i-IL-12p40 ant ibodies (for example, ustekinumab 
[Stelara®]) or anti -IL-23p19 ant ibodies (for example, risankizumab 
[BI-655066], brazikumab [MEDI2070], guselkumab [CNTO 1959], or 
tildrakizumab [MK -3222]) for any  indicat ion, includ ing invest igational use
[14] have known allergies to LY3074828, related compounds, or any  
components of the formulat ion, or hi story  of significant atopy
[15] have an abnormalit y in the 12 -lead ECG that, in the opinion o f the 
investigator, increases the ris ks associated wi th parti cipat ing in the study
[16]have an abnormal blood pressure as determined by the investigator
[17]have a history  or presence of cardiovascular, respiratory , hepat ic, renal, 
gastrointestinal, endocrine, hematological, or neurological disorders 
capable of significant ly altering the absorption, metabolism, or eliminat ion 
of drugs; of const ituting a ri sk when taking the IP; or of interfering wit h the 
interpretati on of  data
[18] have known or ongoing psychiatric disorders deemed clinicall y significant 
by the investigator
[19] regul arly use known drugs of abuse and/or show posit ive findings on drug 
screening
[
20] show evidence of HIV infection and/or posit ive HIV ant ibodies
[21]show evidence of hepatit is C and/or positive hepat itis C ant ibody
I6T-MC-AMBE Clinical Pharmacology Protocol Page 23
LY3074828[22] show evidence of hepatit is B and/or positive hepat itis B surface antigen
[23] are wom en who are lactating
[24]have used or intend to use over -the -counter or prescript ion medications, 
including herbal medicat ions, within 14 days pri or to dosing and for the 
durati on of  the study .  Stable doses of oral contraceptive or 
horm one-replacement therapy  are permi tted, at the discret ion of the 
investigator
[25] have donated blood of more than 500 mL within 1 mo nth prior to screening 
[26] have an average w eekly  alcohol  intake that exceeds 21 units per week 
(males) and 14 units per week (females), have a posit ive test for ethano l, or 
are unwilling to abide by  the alcohol  restri ctions described in Section 6.3.2
(1 uni t = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL 
of distilled spirits)
[27] have a tobacco consumpt ion of more than 10 cigarettes per day  (or 
equivalent), or who are unw illing to abide by the CRU smoking guidelines 
described in Section 6.3.2
[28] have had symptomat ic herpes zoster within 3 mo nths of screening
[29] s how evidence of active or latent TB, as documented by  medical  history , 
examinat ion, and TB testing (negat ive [not indeterminate] 
Quant iFERON ®-TB Gol d test); or have had househo ld contact with a 
person wi th active TB, unless appropriate and documented prop hylaxis 
treatm ent has been given.  Subjects with any history  of active TB are 
excluded fro m the study , regardl ess of previ ous or current TB treatments
[30] have received live vaccine(s), including attenuated live vaccines and those 
administered intranasally,  within 8 weeks of screening, or intend to during 
the study
[31] have been treated with oral steroi ds wi thin 1 month of screening, or intend 
to during the study (mild topical steroid creams/o intments are permitted)
[32] are immunocompro mised
[33] have si gnificant allergies to humanized monoclonal antibodies 
[34] have clinically  significant m ultiple or severe drug allergies, or intolerance 
to topi cal corti costeroi ds, or severe posttreatment hypersensit ivity react ions 
(including, but not limited to, ery thema multiforme major, linear 
immunogl obulin A dermatosis, toxic epidermal necrolysis, or exfo liative 
derm atitis)
[35] have had lympho ma, leukemia, or any  malignancy  within the past 5 years 
except for basal cell or squamous epithelial carcinomas of the skin that 
have been resected with no evidence o f metastati c disease for 3 y ears
[36]have had breast cancer within the past 10 y ears
I6T-MC-AMBE Clinical Pharmacology Protocol Page 24
LY3074828[37] have excessive tattoos over the arm, thigh, or abdomen that would interfere 
with injecti on-site assessments
[38] in the opi nion of the invest igator, are unsuitable for inclusion in the study
6.3. Lifestyle and/or Dietary Requirements
Throughout the study, subjects may undergo medical assessment sand review of compliance with 
requirements before continuing in the study .  
6.3.1. Meals and Dietary Restrictions
Subjects will fast overnight for at least 8 hours before dosing (water is permitted).  Standard 
meals will be provided at all other times while subjects are resident at the CRU, as per the 
CRU’s policy. Fasting is not required prior t o routine safet y laboratory  tests.
6.3.2. Caffeine, Alcohol, and Tobacco
Subjects will not consume caffeinated beverages (decaffeinated beverages are permitted) while 
at the CRU, and for 12 hours prior to admissio n to the CRU.  At other times during the outpatie nt 
period, subj ects will be allowed to maintain their regular caffeine consumpt ion.
Alcoho l consumpt ion is not permitted while at the CRU, and for 12 hours prior to each study 
visit.  At other times, alcoho l consumpt ion should be limited to 2 units per day (1 uni t = 12 oz or 
360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of dist illed spirits).
Subjects who smoke will be advised to not increase their consumpt ion of tobacco products 
during the study .  Subj ects will be expected to refrain fro m smoking while residing in the CRU , 
and to abide by  the CRU sm oking guidelines.
6.3.3. Activity
Subjects will be advised to maintain their regular levels o f physical act ivity/exercise during the 
study , but to refrain from strenuous activit y from 24hours prior to each vi sit and 48 hours pri or 
to any  visit where creatine phosphokinase testing will occur (Day  
-1, Day  8, and Day  29).  While 
certain study  procedures are in progress at the site, subjects may be required to remain recumbent 
or sitting.
6.3.4. Blood and Plasma Donation
Subjects will not donate blood or plasma for 12 weeks fo llowing dosing wit h the study  drug.
6.4. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay not be 
re-screened.
I6T-MC-AMBE Clinical Pharmacology Protocol Page 25
LY30748287.Dosing Regimens
7.1. Dosing Regimens Administ ered
This study  will evaluate the PK, safet y and tol erabili ty of, and pain associated with 125-mgSC 
doses administered using 1-mL PFS or a n invest igational 1-mLAI at 3 different inject ion sites .
Using the invest igational 1-mLAI, the targeted in jection duration will be approximately 5 to 
10
seconds.  Manual injection using the PFS should target an injection durat ion of about 5 to 
10seconds to approximate the inject ion time range for the AI .  Approximate injection durations 
for AIs and PFSs will be obtained using a calibrated stopwatch and recorded in the electronic 
case report form (eCRF).  
Drug and device accountabilit y records will be maintained by  the si te pharmacy .
Table AMBE .2show sthe dosing regimens for the study .
Table AMBE .2. Dosing Regimens Administered
Dosing 
RegimenPFS AI
Reference/testReference
1Reference
2Reference
3Test
1Test
2Test
3
Injection site Arm Thigh Abdomen Arm Thigh Abdomen
Product LY3074828 LY3074828
Dose 125 mg 125 mg
Concentration 125 mg/mL 125 mg/mL
Injection 
volumes1 mL 1mL
Number of 
injections1 1
Injection 
duration5 to 10 seconds per injection 5 to 10 seconds per injection
Formulation 
and 
presentationSolution in a PFS Solution in an AI
Abbreviations:  AI = autoinjector; PFS = pre -filled syringe .
The PFSs and invest igational AIs containing LY3074828 will be supplied fully assembled to the 
clinical site by Lilly.
Inject ions, whether administered by PFS or AI, will be given into the arm, thigh, or lower 
quadrant of the abdo men. Invest igational product will be administered to subjects on -site by  
designated trained clini cal site personnel .  
I6T-MC-AMBE Clinical Pharmacology Protocol Page 26
LY3074828Prior to the PFS or AI inject ion, the invest igator or his/her designee will prepare the subject’s 
skin per Instructi ons for Use (IFU).  Inject ions into the arm , thigh, or abdom en will be 
administered by  invest igative site staff accord ing to the instructions provided by the sponsor.  All 
study  inject ion sites will be marked using a template for size and with a surgical marker in order 
to identify study  inject ion sites for later assessments.   Further informat ion regarding SC 
administrati on will be included in the device IFU for the PFS and in the device IB (which 
contains IFU) for the AI .
In some cases, the site may destroy  the m aterial if, during the invest igative site select ion, the 
evaluator has verified and documented that the site ha s appropri ate facilit ies and wri tten 
procedures to dispose of clinical trial materials. 
7.1.1. Packaging and Labeling
LY3074828 will be supplied by the sponsor or its designee in accordance with current good 
manufacturing process , and labeled according to the country’s regulatory requirements.  All IPs
will be stored, inventoried, reconciled, and returned or destroy ed according to applicable 
regul ations. The fo llowing products will be supplied by  Lilly:
pre-assembled LY3074828 PFSs, 1 mL
pre-assembled invest igational LY3074828 AIs, 
1mL
Each invest igational device will be individually ident ified and labeled according to US 
regul atory  requi rements for investigational devices.
7.2. Method of Treatment Assignment
Subjects will be rando mized toa 1-mL PFS administration to the arm, thigh, or abdomen or a 
1-mLAIadminist rationto the arm, thigh, or abdomen (Table AMBE . 2).
Randomization will be performed using a computer -generated randomizat ion schedule.
7.2.1. Selection and Timing of Doses
The actual  time of all dose administrations will be recorded in the subject ’s eCRF .
7.3. Blinding
This is an open -label study .
7.4. Dose Modification
Dose adjust ments are not permitted in this study .
I6T-MC-AMBE Clinical Pharmacology Protocol Page 27
LY30748287.5. Preparation/Handling/Storage/Accountability
The IPs for this study  will be:
LY3074828 in PFSs
LY3074828 in invest igational AIs
Invest igational product will be stored refrigerated at 2°C to 8°C (36°F to 46°F) in its original 
carton to protect from light.  Invest igational product should not be frozen or shaken.  Sites will 
be required to monitor temperature of the on -site storage co nditions of the IP.  The investigator 
or desi gnee m ust confirm  appropriate tem perature condi tions have been maintained, as 
communicated by  sponsor, during transit for all IP received and any  discrepancies are reported 
and reso lved before use of the study  treatment.
The AIs and PFSs containing LY3074828 should be allowed to warm to room temperature 
before use.  
Only participants enro lled in the study  may receive IP or study  materials, and only authorized 
site staff may supply or administer IP.  All IP shoul d be stored in an environmentally controlled 
and mo nitored (m anual  or autom ated) area in accordance wit h the l abeled storage condit ions 
with access limited to the invest igator and authorized site staff.
The invest igator is responsible for study treatment accountabilit y, reconciliat ion, and record 
maintenance (such as receipt, reconciliat ion,and final disposit ion records).
7.6. Treatment Compliance
The IP will be administered at the clinical site, and documentation of treatment administration 
will occur at the site.
7.7. Concomitant Therapy
Over -the-counter or prescript ion medications, including herbal medicat ion, are not permitted 
within 14 days prior to dosing and throughout the study .  However, stable doses of oral 
contraceptive or hormone -replacement therapy  are permitted at the discretion of the invest igator.
Paracetamo l/acetaminophen (up to 2 g/day) is permitted at the discret ion of the invest igator , but 
shoul d be avoi ded during the 4- hour postdose period when pain assessments are made .  
Addit ional drugs are to be avo ided during the study, unless required to treat an AE.
If the need for concomitant medicat ion arisesper Investi gator di scret ion, continuat ion of the 
subject may be at the discret ion of the invest igator inconsultat ion with a Lilly  clinical 
pharmaco logist (CP) or clinical research physician (CRP).  Any  addi tional medicat ion used 
during the course of the study  must be docum ented.
7.8. Treatment after the End of the Study
This sect ion is not applicable for this study.
I6T-MC-AMBE Clinical Pharmacology Protocol Page 28
LY30748288.Discontinuation Criteria
8.1. Discontinuation from Study Treatment
Randomized subjects who discont inue the study prematurely for any reason should co mplete the 
early  discontinuat ion (ED) procedures as shown in the Schedule of Act ivities(Secti on2).  The 
reason for and the date of discont inuat ion will be collected for all subjects.
8.1.1. Discontinua tion of Inadvertently Enrolled Subjects
If the sponsor or i nvest igator ident ifies a subject wh o did not m eet enrollment cri teria and was 
inadvertent ly enro lled, a discussio n must occur between the Lilly  CP or CRP and the invest igator 
to determine if the subject may  cont inue in the study .  If both agree i t is medically  appropriate to 
continue, the i nvest igator must obtain documented approval fro m the Lilly  CP or CRP to all ow 
the inadvertently enro lled subject to continue in the study.  Any subjects that are inadvertently 
enrolled will be fo llowed for safet y.
8.2. Discontinuation from the Study
Subjects wi ll be discont inued in the fo llowing ci rcum stances:
Enrollment in any other clinical study  involving an IP or enrollment in any other type of 
medical research judged not to be scient ifically or medically co mpat ible with this study
Parti cipation in the study needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, regulations, and good clinical pract ice
The invest igator decides that the subject should be discontinued fro m the study
The subjec t requests to be wi thdrawn from  the study
Subjects who discont inue the study early will have ED procedures performed as shown in the 
Schedule of Act ivities(Secti on 2).
8.3. Subjects Lost to Follow -up
A subject will be considered lost to follow -up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  the study  site.  Sitepersonnel are expected to make 
diligent attempts to contact subjects who fail to return for a scheduled visit or were otherwise 
unable to be fo llowed up by  the si te.
I6T-MC-AMBE Clinical Pharmacology Protocol Page 29
LY30748289.Study Assessments and Procedures
Secti on 2lists the Schedule of Act ivities, detailing the study  procedures and their timing 
(including tolerance limit s for timing).
Appendix 2 lists the clinical laboratory tests that wi ll be perform ed for this study .
Appendix 5 provi des a summary of the maximum  number and vo lume of invasive samples, for
all sampling, during the study .
The specificat ions in this protocol for the timings of safet y and sample co llection are given as 
targets to be achieved wit hin reasonable limits.  Modificat ions may be made to the time po ints 
based upon emerging clinical informat ion.  The scheduled t ime points may be subject to minor 
alterati ons; however, the actual time must be correct ly recorded in the eCRF.  Late collection 
outsi de the st ipulated time allowances or failure to obtain samples due to clinical issues, such as 
probl ems wi th equipment, venous access, or subject default ing on a scheduled procedure, will 
not be con sidere d as protocol  deviati ons but the si te will st ill be requi red to notify  the sponsor in 
writing via a file- note.
Unless otherwise stated in subsect ions below, all s amples collected for specified laboratory  tests 
will be destroy ed wi thin 60 days of receipt of conf irmed test results.  Certain samples may be 
retained for a longer period, if necessary , to com ply with applicable laws, regulat ions, or 
laboratory  certificati on standards.
9.1. Efficacy Assessments
This sect ion isnot applicable to this study .
9.2. Adverse Events
Invest igators are responsible for monitoring the safety of subjects who have entered this study 
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the subject.
The invest igator is responsible for the appropriate medical care of subjects during the study.
Invest igators must document their review of each laboratory  safety  report.
The invest igator remains responsible for fo llowing, through an appropriate health care option, 
AEs that are seri ous or otherwi se medically  important, considered rel ated to the IP or the study .  
The subject should be fo llowed unt il the event resolves, stabilizes with appropriate diagnostic 
evaluat ion, or is reasonably  explained.  The frequency of foll ow-up evaluat ions of the AE is left 
to the di scret ion of the invest igator.
After the informed consent form is signed, study  site personnel will record, via eCRF, the 
occurrence and nature of each subject’s preexist ing conditions.  Addit ionally , site person nel will 
record any  change in the condit ion(s) and the occurrence and nature of any  AEs.  
I6T-MC-AMBE Clinical Pharmacology Protocol Page 30
LY3074828The invest igator will interpret and document whether or not an AE has a reasonable possibilit y 
of being related to study  treatm ent, study  device, or a study  procedur e, taki ng into account 
concomitant treatment or pathologies.  
A “reasonable possibilit y” means that there is a cause and effect relat ionship between the IP, 
study  device ,and/or study  procedure and the AE.
Planned surgeries should not be reported as AEs u nless the underlying medical condit ion has 
worsened during the course of the study .
9.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing:
death
initial or prolonged inpatient hospitalizat ion
a life- threatening experi ence (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in death 
or hospitalization but may jeopardize the patient or may  requi re intervent ion to prevent 
one of the other outcomes listed in the definit ion above
when a condit ion related to the invest igational device (PFS or AI) necessitates medical or 
surgi cal interventi on to precl ude ei ther perm anent impai rment of a body  function or 
perm anent dam age to a body  structure, the seri ous outcom e of “requi red intervent ion” 
will be assigned.
Study  site personnel  must al ert the Lilly  CRP/CP, or i ts desi gnee, of  any SAE as soon as 
practi cally  possible.
Addit ionally , stud y site personnel  must al ert Lilly  Global Patient Safet y(GPS) , or its designee, 
of any SAE wi thin 24 hours of invest igator awareness of the event via a sponsor -approved 
method.  If alerts are issued via telephone, they  are to be immediately fo llowed wi th official 
notification on study -specific SAE forms.  This 24 -hour notificat ion requirement refers to the 
initial SAE informat ion and all fo llow-up SAE inform ation.
Although all AEs are recorded in the eCRF after signing informed consent, SAE reporting to t he 
sponsor begins after the subject has signed informed consent and has received IP.  However, if 
an SAE occurs after signing informed consent, but prior to receiving IP, AND is considered 
Reasonably Possibly Related to a study  procedure then it MUST be re ported.
Invest igators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued fro m and/or com pleted the study  (the subject summary eCRF has been completed).  
However, if the invest igator learns of any SAE, including a death, at any time after a subject has 
I6T-MC-AMBE Clinical Pharmacology Protocol Page 31
LY3074828been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study  treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly . 
Pregnancy (maternal or paternal exposure to IP) does not meet the definit ion of an AE.  
However, to fulfill regulatory  requi rements any  pregnancy  should be reported following the SAE 
process to collect data on the outcome for both mother and fetus.
9.2.1.1. Adverse Device Effects
Any AE believed to have a reasonable possibilit y of being related or associated to an issue with 
the AI or PFS , such as a malfunct ion or a deficiency, is considered an adverse device event.  
These events must be clearly indicated as such in the eCRF, and reported to the sponsor. A 
Product Complaint shoul d also be reported.
For the purpose of this protocol, “unant icipated” serious adverse device effect means any SAE
alleged to have a reasonable possibilit y to be associated or related to the device, which was not 
previously defined as ant icipated in study  docum ents, such as the device IB or IFU .  The SAE 
relatedness m ust be cl early  indicated as such in the eCRF, and re ported to the sponsor within 
24hours of site knowledge o f the event.  A P roduct Complaint shoul d also be reported.
9.2.1.2. Adverse Events of Special Interest
The fo llowing AEs of special interest will be used to determine the safet y and tol erabilit y of 
LY3074828 inject ions administered by  either PFS or investigational AI in this clinical study .
Adverse events of special intere st for LY3074828 are:
infect ion
ISRs
allergic/hypersensit ivity react ions
If infections, ISRs, or allergic/hypersensit ivity reacti ons are reported, sites will provide details on 
these events as instructed on the eCRF.  Investigators will also educate subjects about the 
symptoms of allergic/hypersensit ivity react ions and will provide instructions on dealing wit h 
these reactions.  A blood s ample will be collected when possible for any subject who experiences 
an AE of allergic/hypersensit ivity react ion during the study .
9.2.1.3. Suspected Unexpected Serious Adverse Reactions 
Suspected une xpected seri ous adverse react ions (SUSARs) are serious events that are not listed 
in the IB and that the investigator reports as related to IPor procedure.  Lilly  has procedures that 
will be fo llowed f or the recording and expedited reporting of SUSARs that are consistent with 
global regulat ions and the associated detailed guidances.
9.2.2. Complaint Handling
Lilly co llects PCs on IPs and drug delivery systems used in clinical trials in order to ensure the 
safet y of study  participants, m onitor quali ty, and to facilitate process and product improvements.
I6T-MC-AMBE Clinical Pharmacology Protocol Page 32
LY3074828Subjects should be instructed to contact the invest igator as soon as possible if he or she has a 
complaint or problem wit h the IP or drug delivery system so that the situation can be assessed.  
A PFS or AI that is associated with a product quality  issue or complaint must be returned to 
Lilly.
The invest igator or his/her designee is responsible for report ing and handling the fo llowing 
aspects of the P roduct Complaints (PC) process in accordance with instructi ons on the Product 
Com plaint s form, and the instructi ons provi ded for this study :
recording a complete descript ion of the PC reported and any associat ed AEs using the 
study -specific co mplaint form s provi ded for this purpose
forwarding via email or fax the com pleted Product Complaint formwithin 24 hours to 
Lilly or i ts desi gnee if associated to an SAE, otherwise within 1 business day .
If the invest igato r is asked to return the product for invest igation, he/she will return a copy  of the
completed Product Complaint formwith the product.
9.3. Treatment of Overdose
For the purposes of this study , an overdose of LY3074828 is considered any dose higher than the 
dose assigned through rando mizat ion.
There i s no specific antidote for LY3074828.  In the event of an overdose, the subject should 
receive appropriate supportive care and any AEs should be documented.
Refer to the study  drug IB for further details.
9.4. Safety
9.4.1. Laboratory Tests
For each subject , laboratory  testsdetailed in Appendix 2 shoul d be conducted accordi ng to the 
Schedule of Activities (Secti on2).
Lilly or i ts desi gnee will  provide the investi gator wi th the resul ts of laboratory  tests analyzed by  
a central  vendor, if a central vendor is used for the study
.
9.4.2. Vital Signs
For each subject, vital sign measurements (blood pressure, pulse rate, and temperature) should be 
conducted according to the Schedule of Activit ies (Secti on 2).  Addit ional vital signs may be 
measured during the study  if warranted.
Blood pressure and pulse rate should be measured after at least 5 minutes supine.
If orthostatic measurements are requ ired, subjects should be supine for at least 5 minutes and 
stand for at least 2 minutes.
I6T-MC-AMBE Clinical Pharmacology Protocol Page 33
LY3074828If the subject feels unable to stand, supine vital signs only  will be recorded. 
Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or 
posture -induced symptoms.  
9.4.3. Electrocardiograms
For each subject, a single 12-lead digital ECG will be collected according to the Schedule of 
Activities (Sect ion 2).  El ectrocardi ograms m ust be recorded before collecting any  blood 
samples.  Subjects must be supine for at least 5 minutes before ECG collect ion and remain 
supine but awake during ECG collect ion.  El ectrocardi ograms m ay be obtained at addit ional 
times ,when deemed clinically necessary .  All ECGs recorded shoul d be stored at the 
investigat ional site.
Electrocardiograms will be interpreted by  the investi gator o r qualified designee at the site as 
soon after the time o f ECG collect ion as possible, and ideally while the subject is st ill present, to 
determine whether the subject meets entry  criteria at the rel evant visit(s) and for immediate 
subject management, shou ld any clinically relevant findings be identified.  
If a clinically significant finding is ident ified (including, but not limited to, changes in QT/QTc 
interval  from baseline) after enrollment, the investigator will determine if the subject can 
continue i n the study .  The invest igator, or qualified designee, is responsible for determining if 
any change in subject management is needed, and must document his/her review of the ECG 
printed at the time of co llection.  
Any clinically  significant findings from E CGs that resul t in a di agnosis and that occur after the 
subject receives the first dose of the IP should be reported to Lilly, or its designee, as an AE via 
eCRF.
9.4.4. Other Tests
9.4.4.1. Tuberculosis Testing
Subjects will be tested as indicated in the Schedule of Act ivities (Section 2) for evidence of 
active or latent TB using the QuantiFERON -TB Gol d test.  If the test is indeterminate, 1 retest i s 
allowed.  If the retest i s indeterminate, the subject will be excluded fro m the study .
Subjects who have had househo ld contact with a person with active TB must be excluded unless 
appropriate and documented prophylaxis treatment for TB has been co mpleted.
Subjects with any history  of active TB are excluded fro m the study , regardl ess of previous or 
current TB treatments.
9.4.4.2. Injection Duration Assessments
Inject ion duration will be measured by a calibrated stopwatch by  qualified trained study  staff.  
The durati on of  injecti on for the PFS will be defined as the time between when the plunger rod is 
pressed down and when all o f the LY3074828 solution is injected.  The duration of inject ion for 
the AI will be defined as the time between the first audible click after the injection button is 
I6T-MC-AMBE Clinical Pharmacology Protocol Page 34
LY3074828pressed and the last audible click, which indicates that the needle has retracted and the inject ion 
is co mplete.  
9.4.4.3. Injection-S ite Assessments
Inject ion site finding s(including ery thema, induratio n, pruritus, and edema) will be captured on 
a sep arate ISR form,asindicated in the Schedule of Act ivities (Secti on 2).
Data from injection site evaluat ions (including pain) which are recorded as a result of specific 
questionnaire /s will not be reported as AEs. If the investigator determines that the ISR is
clinically significant or if it is an unso licited event (vo lunteered by  subject), the event will be 
captured i n the subject ’s eCRF as an AE .  
If an ISRis deemed to be an AE, the ISRform will be used to capture specific informat ion about 
this react ion (eg, degree and area of erythema).
Inject ion
-site tenderness on contact reported by subjects may be recorded as an AE, but is not 
requi red to be captured in ISR form.
9.4.4.4. Bleeding Assessment
All injecti on si tes will  be observed at the times indicated in the Sch edule of Act ivities (Section 2) 
by the investigator or designee, and the presence of visible bleeding will be recorded on the 
eCRF.  A bandage may be pl aced on the inject ion site after assessment.
9.4.4.5. Injection
-Site Pain
Pain measurements will be quant ified using the 100- mm validated VAS pain score for all 
subjects, whether or not they  report i njecti on pain.  The VAS is a well -validated tool 
(Williamso n and Hoggart 2005) to assess inject ion-site pain; i t is presented as a 100 -mm line 
anchored by  verbal descriptors, usually “no pain” and “worst possible pain.”  The subject will be 
asked to rate any  pain at the injection site on a scale of 0 to 100 mm on th e line immediately  
(within 1minute) fo llowing the inject ion and at the time points listed in the Schedule of 
Activities (Section 2).
9.4.5. Safety Monito ring
The Lilly CPor CRP /scientist will mo nitor safet y data throughout the course of the study .
Lilly will review SAEs wit hin time frames mandated by co mpany procedures.  The Lilly CPor 
CRP will periodically review the fo llowing data:
trends in safety  data
laboratory  analytes
AEs, including monitoring of incidence of any  nature of any  infect ions, and ISRs
PCs
I6T-MC-AMBE Clinical Pharmacology Protocol Page 35
LY3074828When appropriate, the Lilly CP or CRP will consult with the funct ionally  independent GPS 
therapeuti carea physician, GPS device physician, or GPS clinical research scientist.
9.4.5.1. Hepatic Safety
If a study  subject experiences elevated alanine aminotransferase (ALT) ≥3× upper limit of 
norm al (ULN), al kaline phosphatase (ALP) ≥2× ULN, or elevated total bilirubin (TBL) 
≥2×ULN, liver tests ( Appendix 4 ) shoul d be repeated wi thin 3 to 5 days including ALT, 
aspartate aminotransferase, ALP, TBL, direct bilirubin, gamma -glutamyl transferase, and 
creatine phosphokinase to c onfirm the abnorm ality and to determine if it is increasing or 
decreasing.  If the abnormalit y persists or worsens, clinical and laboratory  monitoring shoul d be 
initiated by  the invest igator based on consultation with the Lilly CP or CRP.  Monitoring shoul d 
continue until levels normalize and/or are returning to approximate baseline levels. 
Addit ional safet y data should be co llected if 1 or more of the following condit ions occur: 
elevation of serum  ALT to ≥5×ULN on 2or more consecut ive blood tests
elevated serum  TBL to ≥2×ULN (except for cases of known Gilbert’s syndrome)
elevation of serum  ALP to ≥2×ULN on 2 or more consecut ive blood tests 
hepat ic event considered to be an SAE
9.4.5.2. Monitoring of Hypersensitivity Reactions
There i s a risk of systemic hyper sensi tivity react ions wit h any  biological  agent, including acute 
anaphylaxis and delayed hypersensit ivities to LY3074828.  Symptoms and signs that may occur 
as part of these hypersensit ivity react ions include, but are not limited to: fever, chills, jo int and 
muscle pain, rash, itching, urticaria, dizziness, headache, throat irritation, and shortness of 
breath.  Less co mmo nly, life -threatening anaphylactic react ions may occur, which may include 
vascular collapse and/or respiratory  com promise.
All subjects w ill be closely mo nitored for si gns and symptom s of hypersensit ivity react ions 
following administration of the study  drug, and appropriate medical care should be provided.  
Hypersensi tivity react ions will be evaluated by examinat ion of TEAEs and SAEs, and t hrough 
the use of a fo llow-up form which will be com pleted by  the invest igator.  Potential 
hypersensit ivity events will be evaluated by a Lilly CRP based on accepted criteria (Sampson et 
al. 2006 ).
In the event of drug hypersensit ivity react ions (immediate or non -immediate), addit ional samples 
will be collected as close to the onset of the event as possible, at the resolut ion of the event, and
approximately  30 days following the event to evaluate ADA , PK, and additional expl oratory  
biomarkers of hypersensit ivity which coul d include try ptase, com plement levels and cytokine 
measurements. Instructions for the collection and handling of blood samples will be provi ded by  
the sponsor. The actual date and time (24 -hour clock time) of each sampling will be recorde d.
I6T-MC-AMBE Clinical Pharmacology Protocol Page 36
LY30748289.5. Pharmacokinetic s
At the visit s and t imes specified in the Schedule of Act ivities (Secti on 2), venous blood samples 
of approximately  2mL each wil l be co llected to determine the serum concentrations of 
LY3074828.  A maximum o f 3 sam ples m ay be collected at addit ional time points during the 
study  if warranted and agreed upon between both the invest
igator and sponsor.  Instructions for 
the collect ion and handling of blood samples will be provided by  the sponsor.  The actual  date 
and time (24- hour cl ock time) of each sampling will be recorded.
9.5.1. Bioanalysis
Samples will  be analyzed at a l aboratory  approved by  the sponsor and stored at a facilit y 
designated by  the sponsor.  Concentrations of LY3074828 will be assayed using a validated 
enzyme- linked immunosorbent assay.  
Bioanaly tical samples collected to m easure IP concentrations will be retained for a maximum o f 
1 year fo llowing last subject visit for the study .  During this t ime, samples remaining after the 
bioanalysis may  be used for exploratory  metabolism or exploratory analyses such as 
bioanalyt ical assa yvalidati on or cross -validation exercises.
9.6. Pharmacodynamic s
9.6.1. Immunogenicity Assessments
Blood sam ples f or immunogenicit y testing will  be collected to determine ant ibody  producti on 
against LY3074828, as specified in the Schedule of Act ivities (Secti on 2).  Addit ional samples 
may be collected if there is a possibilit y that an AE is immunol ogically  mediated.  If addi tional 
immunogenicit y testing sa mples are taken, matching PK sample co llections will also be required.  
Immunogenicit y will be assessed by  a validated assay  designed to detect ADAs in the presence 
of the IP.  Ant ibodies may be further characterized and/or evaluated for their abilit y to n eutralize 
the activit y of the IP.  
A risk -based approach will be used to monitor subjects who develop TE -ADAs during and 
following treatm ent wi th LY3074828.
Subjects will have ADA sampling at the visits specified in the Schedule o f Activities (Secti on 2).
Subjects who have clinical sequelae that are considered poten tially related to the presence of 
TE
-ADA may be asked to return for addit ional fo llow-up testing.
Samples will  be retained for a m aximum  of 15 y ears after the last subject visit, or for a shorter 
period if local  regulat ions and institutional review boards (IRBs) allow, at a facilit y selected by  
the sponsor.  The duration allows the sponsor to respond to future regulatory  requests related to 
the IP.  Any  samples remaining after 15 years will be destroy ed.
I6T-MC-AMBE Clinical Pharmacology Protocol Page 37
LY30748289.7. Genetics
A blood sam ple will be collected for pharmacogenet ic analysis as specified in the Schedule o f 
Activities (Secti on 2), where l ocal regulat ions allo w.  
Samples will  notbe used to conduct unspecifie d disease or populat ion genet ic research either 
now or in the future.  Samples will be used to investigate variable exposure or response to 
LY3074828 and to investigate genetic variants thought to play  a rol e in autoimmune and 
inflammatory  diseases.  Asses sment of variable response may include evaluat ion of AEs or 
differences in efficacy.  
All samples will be coded with the subject number.  These samples and any  data generated can 
be linked back to the subject only by the invest igative site personnel.  
Samples will be retained for a maximum o f 15 years after the last subject visit, or for a shorter 
period if local  regulat ions and/or IRB impose shorter time limit s, for the study  at a f acility 
selected by  Lilly or i ts desi gnee.  This retention period enables use of new techno logies, response 
to regulatory  quest ions, and invest igation of variable response that may  not be observed unt il 
later in the development of LY3074828 or after LY3074828 is commercially available.  
Molecular techno logies are expected to i mprove during the 15
-year storage period and therefore 
cannot be specifically  named.  However, exist ing approaches include who le geno me or exome 
sequencing, geno me wide association studies, multiplex assays, and candidate gene studies.  
Regardless of techn ology utilized, data generated will be used only  for the specific research 
scope described in this sect ion.
9.8. Biomarker s
This sect ion is not applicable for this study.
9.9. Health Economics
Thissection is not applicable for this study.
I6T-MC-AMBE Clinical Pharmacology Protocol Page 38
LY307482810. Statistical Considerations and Data Analysis
10.1. Sample Size Determination
Approximately 66 subjects will be enrolled with a target of 60 subjects com pletingthe study  
(10completers per treatment). 
Data from AMAL ( 2x 1-mL dose sof 125 mgLY3074828) and AMAE ( 2x 1-mL PFS dose sof 
125 m gLY3074828) studi es showed that the geometric coefficient of variation ranged fro m 55% 
to 40% for the PK measurements ( ie, area under the concentration versus time curve [ AUC ]from 
time zero to infinit y [AUC (0-∞) ], AUC from time zero to time t, where t is the last sam ple wi th a 
measurable concentration [ AUC (
0-tlast) ], and maximum observed drug concentration [C max]).
Thus, the geometric coefficient of variat ion was assumed to be 55% when calculat ing precisio n.
A sample size o f 60 subjects will provide a precision (ie, half-width of 90% of confidence 
interval  [CI]with a coverage probabilit y of 90%) , in log scale, of approximately  0.48 f or 
thegeom etric means rati o of reference versus test for AUC(0- ∞), AUC(0 -tlast), and C max. 
Equivalently, there is a 90% probabilit y that the distance between the lower limit of the 90% CI 
and the point estimate of the geometric means rat iois not larger than 38%.
Subjects who are randomized but not administered treatment, or subjects (maximum of
2 subjects per dose regi men arm ) that are administered treatment but do not have PK and ADA 
samples co llected up to and including Day 57, may be replaced to ensure that approximately 
10subjects from each treatment arm may co mplete the study .
10.2. Populations for Analyses
10.2.1. Study Partic ipant Disposition
A detailed description o f subject disposit ion will be provided at the end of the study . 
10.2.2. Study Participant Characteristics
The subject’s age, sex, weight, BMI, height, race/subrace, and other demographic data will be 
summarized by  dosing regimen and overall.
10.3. Statistical Anal yses
Statistical analysis o f this study  will be the responsibilit y of Eli Lilly and Com pany  or its 
designee.
Pharmacokinet ic analyses will be conducted on the full analysis set.  This set includes all data 
from all rand omized subjects receiving the dose of LY3074828 with evaluable PK data.  Safet y 
analyses will be conducted for all subjects receiving a dose of LY3074828, whether or not they  
completed all  protocol  requi rements.
I6T-MC-AMBE Clinical Pharmacology Protocol Page 39
LY3074828Addit ional exploratory  analyses of the data will be conducted as deemed appropriate.  Study  
resul ts may be pool ed wi th the resul ts of other studies for populat ion PK analysis purposes to 
avoid issues with post -hoc analyses and inco mplete di sclosures of analyses.  
No adj ustments for multiple com parisons will be made.
10.3.1. Safety Analyses
10.3.1.1. Clinical Evaluation of Safety
All IP and protocol procedure AEs and PCs will be listed, and if the frequency o f events allows, 
safet y data will be summarized using descriptive methodology .
The incidence of symptoms for ea ch treatment will be presented by severit y and by associ ation 
with IP as perceived by the invest igator.  Symptoms reported to occur prior to study entry will be 
distinguished from those reported as new or increased in severit y during the study .  Each 
sympt om will be classified by  the m ost sui table term fro m the medical regulatory  dictionary.
The number of IP -and device -related SAEs and any  related PCs will  be reported.
10.3.1.2. Statistical Evaluation of Safety
10.3.1.2.1. Injection -Site Pain
The intensit y of pain at theinject ion site within 1 minute of the end of inject ionand 5minutes 
after the end of the inject ionwill be evaluated, as reported by  the subject and m easured 
according to the 0 -to 100 -mm VAS.  VAS scores will be categorized into mild(0-to 30 -mm), 
moderate(31-to 70 -mm), and severe (71-to 100 -mm).  Assessments will also be performed at 
15, 30, 60, and 120 minutes post -inject ion; however, the primary  endpoint swill be the 1-and 
5-minute assessment s. 
Descript ive statistics will be used to summarize th e intensit y of pain at each t ime point.
A linear fixed
-effects m odel will be used to analyze the 1-and 5 -minute post-inject ion pain VAS 
score sseparately .  The m odel will include device and injection locat ion as fixed effect s.  The 
least squares (LS) means and differences in LS means will be presented along wit h the 
corresponding 90% CI overall and by locat ion as subgroups .  The di stributi on of  the data will be 
explored prior to analysis to determine whether data transformat ion is required.  It is poss ible 
that the pain scores will be 0 ,so if the distribut ion of the data implies that a log -transformat ion is 
requi red then the score may be updated to log(VAS+1) to allow for the inclusio n of the 0 values 
in the analysis.   
If the assumpt ions of this model appear vi olated, a non -param etric m ethod may  
be used.
10.3.1.2.2. Duration of Injection
The durati on of  the inject ion (measured in seconds) will be summariz ed for each drug delivery  
device for each inject ion site .
I6T-MC-AMBE Clinical Pharmacology Protocol Page 40
LY307482810.3.1.2.3. Injection -Site Assessments
The incidence of the follow ing AEs will be listed and summarized for each drug delivery device 
for each inject ion site : erythema, indurat ion, pruritus, and edema .  Occurrence of bleeding will 
be listed.   
10.3.1.2.4. Statistical Evaluation of Other Safety Parameters
Other safet y param eters that will be assessed include clinical laboratory  param eters and vital 
signs.  The parameters and changes fro m baseline (predose) ,where appropriate, will be listed 
and summarized using standard descriptive statist ics.  Addit ional analyses will be performed if
warranted upon review of the data.
10.3.2. Pharmacokinetic Analyses
10.3.2.1. Pharmacokinetic Parameter Estimation
Pharmacokinet ic parameter estimates for LY3074828 will be calculated by standard 
nonco mpart mental methods of analysis.
The primary parameters for analysis wil l be AUC(0 -∞), AUC(0 -tlast), and C maxfor LY3074828.  
The secondary  param eter for analysis will be the time to maximum observed drug concentration 
(tmax) of LY3074828.  Other noncompart mental param eters, such as half-life associated with the 
terminal rate constant ( t1/2), apparent total body clearance of drug calculated after extra- vascular 
administration (CL/F), and apparent volume o f distributi on during the terminal phase after 
extra -vascular administration (V z/F), may  be reported.
10.3.2.2. Pharmacokinetic Statist ical Inference
The AUC(0 -∞), AUC(0 -tlast), and C maxwill be log-transformed and analyzed using alinear 
fixed -effects m odel.  The m odel will include device and injection locat ion as fixed effect s.  The 
dosing reg imen differences between AI and PFS administ rationswill be back -transform ed to 
present the ratios of geometric LS means and the corresponding 90% CI .  Comparisons will be 
made between the 2 devices and then between the 3 injection locat ions.
The t maxof LY3074828 between AI and PFS administration swill be analyzed using a Wilcoxon 
rank sum test.  Estimates of the median difference, 90% CIs, and p -values fro m the Wilcoxon 
rank sum test will be calculated.
Addit ional PK analyses may be conducted if deemed appropriate.
10.3.3. Pharmacodynamic Analyses
This se ction is not applicable for this study.
10.3.4. Pharmacokinetic/Pharmacodynamic Analyses
This sect ion is not applicable for this study.
I6T-MC-AMBE Clinical Pharmacology Protocol Page 41
LY307482810.3.5. Evaluation of Immunogenicity
The frequency of format ion of antibodies to LY3074828 will be determined.  
Treatment -emergent ADAs are those that are induced or boosted by  exposure to study  drug, wi th 
a 4-fold or greater increase in t iter com pared to baseline if ADAs were detected at baseline, or a 
titer 2-fold greater than the minimum required dilution (1:10) if no ADAs were detected at 
baseline.
If a neutralization assay is performed, the frequency o f neutralizing ant ibodies will be 
determined.  The relat ionship between the presence (or absence) of ant ibodies and clinical 
param eters (AEs) will be assessed.  Likewise, the relat ionship between the presence of 
antibodies and the PK parameters orconcentrations of LY3074828 may be assessed if deemed 
appropriate.
10.3.6. Data Review During the Study
Data m ay be accessed and analyzed while the trial is ongoing, but no changes to the study  design 
are planned.  An assessment committee will not be formed.
Available safet y data will be reviewed at approximately Day  30of the l ast cohort dosed in order 
to revi ew emerging safet y and tol erabilit y data.
10.3.7. Interim Analyses
No formal interim analysis will  be conducted. Data may  be accessed as described in 
Secti on10.3.6 .
I6T-MC-AMBE Clinical Pharmacology Protocol Page 42
LY307482811. References
Cornelissen F, Asmawidjaja PS, Mus AM , Corneth O, Kikly K, Lubberts E. IL -23 dependent and 
independent stages of experimental arthrit is: no clinical effect of therapeutic IL -23p19 
inhibit ion in co llagen -induced arthrit is. PLoS One . 2013;8(2):e57553.
Crow JM . Therapeutics: silencing psoriasis. Nature. 2012;492(7429):S58- S59.
Di Cesare A, Di  Megli o P, Nestl e FO. The IL -23/Th17 axis in the immunopathogenesis of 
psori asis. J Invest Dermatol. 2009;129(6):1339 -1350.
Lew W, Bowcock AM, Krueger JG. Psoriasis vulgaris: cutaneous lympho id tissue support s 
T-cell act ivation and “Type 1” inflammatory gene expressio n. Trends Immunol . 
2004;25(6):295 -305.
Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med . 2009;361(5):496 -509.
Perera GK, Di Meglio P, Nestle FO. Psoriasis. Annu Rev Pathol. 2012;7:385 -
422.
Ruutu M, Thomas G, Steck R, Degli- Espost i MA, Zinkernagel MS, Alexander K, Velasco J, 
Strutton G, Tran A, Benham H, Rehaume L, Wilson RJ, Kikly K, Davies J, Pettit AR, Brown 
MA, McGuckin MA, Tho mas R. β -glucan tri ggers spondylarthrit is and Crohn's disease -like 
ileitis in SKG mice. Arthritis Rheum . 2012;64(7):2211 -2222.
Sampson HA, Muñoz -Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, Brown 
SG, Camargo CA Jr, Cy dulka R, Galli SJ, Gidudu J, Gruchalla RS, Harlor AD Jr, Hepner DL, 
Lewis LM, Lieberman PL, Metcalfe DD, O'Connor R, Muraro A, Rudman A, Schmitt C, 
Scherrer D, Simons FE, Thomas S, Wood JP, Decker WW. Second symposium on the 
definit ion and management of anaphylaxis: summary  report -Second National Institute of 
Allergy  and Infecti ous Disease /Food Allergy  and Anaphylaxis Network symposium. J Allergy 
Clin Immunol . 2006;117(2):391 -397.
Steinman L. A brief history  of T(H)17, the first major revisio n in the T(H)1/T(H)2 hy pothesis of 
T cell -mediated tissue damage. Nat Med .2007;13(2):139 -145.
Weave r CT, Hatton RD, Mangan PR, Harrington LE. IL -17 family cytokines and the expanding 
diversit y of effector T cell lineages. Annu Rev Immunol . 2007;25:821-852.
Williamson A, Hoggart B. Pain: a review o f three commo nly used pain rat ing scales. J Clin 
Nurs . 2005;14(7):798 -804.
I6T-MC-AMBE Clinical Pharmacology Protocol Page 43
LY3074828Appendix 1. Abbreviations and Definitions
I6T-MC-AMBE Clinical Pharmacology Protocol Page 44
LY3074828Term Definition
ADA anti-drug antibody
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.
AI autoinjector
ALP alkaline phosphatase
ALT alanine aminotransferase
AUC area under the concentration versus time curve
AUC(0 -∞) area under the concentration versus time curve from time zero to infinity
AUC(0 -tlast) area under the concentration versus time curve from time zero to time t, where t is the last 
sample with a measurable concentration
BMI body mass index
CI confidence interval
Cmax maximum observed drug concentration
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all the study -related requirements, good clinical practice (GCP) requirements, 
and the applicable regulatory requirements.
confirmation A process used to confirm that laboratory test results meet the quality requirements defined 
by the laboratory generating the data and that Lilly is confident that results are accurate.  
Confirmation will either occur immediately after initial testing or will require that samples 
be held to be retested at some defined time point, depending on the steps required to obtain 
confirmed results.
CP clinical pharmacologist
CRP clinical research physician
CRU clinical research unit
ECG electrocardiogram
eCRF electronic case report form
ED early  discontinuation
I6T-MC-AMBE Clinical Pharmacology Protocol Page 45
LY3074828enroll The act of assigning a subject to a treatment.  Subjects who are enrolled in the study are 
those who have been assigned to a treatment.
enter Subjects entered into a study are those who sign the informed consent form directly or 
through their legally acceptable representatives.
GCP good clinical practice
GPS Glob al Patient Safety
HIV human immunodeficiency virus
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmoni sation
IFU Instructio ns for Use
IL interleukin
informed consent A process by which a subject voluntarily confirms his or her willingness to participate in a 
particular study, after having been informed of all aspects of the study that are relevant to 
the subject’s decision to participate.  Informed consent is documente d by means of a 
written, signed and dated informed consent form.  
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
IP investigational product:  A pharmaceutical form of an active ingredient or placebo being 
tested or used as a reference in a clinical study, including products already on the market 
when used or assembled (formulated or packaged) in a way different from the autho rized 
form, or marketed products used for an unauthorized indication, or marketed products used 
to gain further information about the authorized form.
investigator A person responsible for the conduct of the clinical study at a study site.  If a stu dy is 
conducted by a team of individuals at a study site, the investigator is the responsible leader 
of the team and may be called the principal investigator.
IRB institutional review board
ISR injection -site reaction
IV intravenous(ly)
LS least square s
open-label A study  in which there are no restrictions on knowledge of treatment allocation, therefore 
the investigator and the study participant are aware of the drug therapy received during the 
study.
PC product complaint
I6T-MC-AMBE Clinical Pharmacology Protocol Page 46
LY3074828PFS pre-filled syringe
PK pharmacokinetic(s)
randomize The process of assigning subjects/patients to an experimental group on a random basis.
SAE serious adverse event
SC subcutaneous(ly)
screen The act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical study.  
SUSARs suspected unexpected serious adverse reactions 
TB tuberculosis
TBL total bilirubin
TE-ADA treatment -emergent anti -drug antibody
TEAE treatment -emergent adverse event:  Any untoward medical occurrence that emerges during 
a defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state, and does n ot necessarily have to have a causal relationship with this 
treatment .
Th T helper
tmax time to maximum observed drug concentration
ULN upper limit of normal
VAS visual analog scale
I6T-MC-AMBE Clinical Pharmacology Protocol Page 47
LY3074828Appendix 2. Clinical Laboratory  Tests
Safety Laboratory Tests
Hematology a Clinical Chemistry a
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Calcium
Mean cell volume Phospho rus
Mean cell hemoglobin Glucose (random)
Mean cell hemoglobin concentration Blood urea nitrogen (BUN)
Leukocytes (WBC) Uric acid
Cell morphology Total cholesterol
Absolute counts of: Total protein
Neutrophils Albumin
Lymphocy tes Total bilirubin c
Monocytes Alkaline phosphatase (ALP)
Eosinophils Aspartate aminotransferase (AST)
Basophils Alanine aminotransferase (ALT)
Platelets Creatinine
Creatine phosphokinase (CPK) d
Urinalysis a Ethanol testing e
Specific gravity Urine drug screen e
pH QuantiFERON -TB Gold test a,f
Protein
Glucose Serology f
Ketones Hepatitis B surface antigen
Bilirubin Hepatitis C antibody
Urobilinogen HIV antibodies
Blood
Nitrite Serum pregnancy  test g,h
Microscopic examination of sediment b Hormone panel
Follicle -stimulating hormone f,i
Abbreviations:  HIV = human immunodeficiency virus; RBC = red blood cells; TB = tuberculosis; WBC = white 
blood cells.
aResults will be validated by the local laboratory at the time of initial testing.
bIf clinically indicated, per investigator’s discretion.
cIf total bilirubin is elevated, direct bilirubin and indirect bilirubin may be measured.
dNot collected routinely as part of clinical chemistry panel. Only collected when specified in Schedule of 
Activities (Section 2).
eUrine drug scre en and ethanol level (determined via breath
, blood ,or urine testing) will be performed locally at 
screening and on Day -1 during admission to the clinical research unit.  May be repeated at the discretion of the 
investigator . 
fPerformed at screening onl y.
gFor all females at screening, and only for women of childbearing potential at sampling time points thereafter.
hRefer to Section 2for specific sampling timing.
iTo confirm postmenopausal status (see Section 6.1,inclusion criterion 1b) 
I6T-MC-AMBE Clinical Pharmacology Protocol Page 48
LY3074828Appendix 3. Study  Governance, Regulatory  and Ethical 
Considerations
Informed Consent
The invest igator is responsible for:
ensuring that the subject understands the nature of the study ,the potential risks and 
benefits of part icipating in the study , and that thei r parti cipat ion is vo luntary.
ensuring that informed consent is given by each subject or legal representative.  Thi s 
includes obtaining the appropriate signatures and dates on the informed consent form 
(ICF) prior to the performance of any protocol  procedures and prior to the administration 
of investigational product.
answering any quest ions the subject may  have throughout the study  and sharing in a 
timely  manner any  new inform ation that m ay be relevant to the subject ’swillingness to 
continue his or her participat ion in the study .
provi ding a copy  of the ICF to the parti cipant or the participant’s legal representative and 
retaining a copy  on file .
Recruitment
Lilly or i ts desi gnee is responsible for the central recruit ment strategy  for subject s.  Individual 
investigators may have addit ional local requirements or processes.   Study -specific recruit ment 
materi al should be appro ved by Lilly.
Ethical Review
The invest igator must give assurance that the institutional review board ( IRB) was properly 
constituted and convened as required by Internat ional Council for Harmonisation ( ICH)
guidelines and other applicable laws and regulations.
Docum entati on of  IRB approval o f the protocol  and the ICF must be provided to Lilly  before the 
study may begin at the investigative site(s).  Lilly  or its representatives must approve the ICF 
before i t is used at the invest igative site(s).  All ICFs must be compliant with the ICH guideline 
on good clinical practice ( GCP ).
The study  site’s IRB(s) shoul d be provi ded wi th the f ollowing:
the current Invest igator’s Brochure and updates during the course of the study
ICF
relevan t curri cula vi tae.
I6T-MC-AMBE Clinical Pharmacology Protocol Page 49
LY3074828Regulatory Considerations
This study  will be conducted in accordance wit hthe protocol and with :
1)consensus ethics pri nciples derived fro m internat ional ethics guidelines, 
including the Declarat ion of Helsinki and Council for International 
Organizat ions of Medical Sciences Internat ional Ethical Guidelines 
2)applicable ICH GCP Guidelines 
3)applicable laws and regulations .
Some of the obligat ions of the sponsor will be assigned to a third-party  organi zation.
Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .  
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly representative.
Final Report Signature
The invest igator or designee will sign the clinical study report for this study, indicat ing 
agreem ent wi th the analyses, results, and conclusio ns of the report.
The sponsor’s responsible medical o fficer and statistician will sign/approve the final clinical 
study  report for this study , confirming that, to the best of his or her knowledge, the report 
accurately describes the conduct a nd results of the study.
Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate
provi detraining to i nstruct the invest igators and study  coordinators.  This training will 
give instruction on the protocol, the complet ion of the electronic case report forms 
(eCRFs ), and study  procedures
make periodic visit s to the study  site
be available for consultation and stay  in contact wi th the study  site personnel by  mail, 
telephone, and/or fax
review and evaluate eCRF data and/or use standard computer edits to detect errors in data 
collect ion
conduct a qualit y review of the database .
I6T-MC-AMBE Clinical Pharmacology Protocol Page 50
LY3074828In addit ion, Lilly or its representatives willperiodically check a sample of the subject data 
recorded against source documents at the study  site.  The study  may be audi ted by  Lilly and/or 
regul atory  agencies at any  time.  Invest igators will be given notice before an audit occurs.
The invest igator wi ll keep records of all original source data.  This might include laboratory  
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable IRBs with direct access to the original source 
docum ents.
Data Collection Tools/Source Data
An electronic data capture sy stem  will be used in this study .  The site must define and retain all 
source records and must maintain a record of any data where source data are directly entered int o 
the data capture system.
Data Protection
Data systems used for the study  will have control s and requi rements in accordance wit h local 
data protecti on law.  
The p urpose and use of subject personal information collected will be provided in a written 
docum ent to the subject by  the s ponsor .
Study and Site Closure
Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly  or its desi gnee , the invest igator, or the IRB
of the study  sitejudges it necessary for medical , safet y, regulatory , or oth er reasons consistent 
with applicable l aws, regul ations, and GCP.
Discontinuation of the Study
The study  will be discontinued if Lilly or its designee judges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws, regul ations, and GCP.
I6T-MC-AMBE Clinical Pharmacology Protocol Page 51
LY3074828Appendix 4. Hepatic Monitoring Tests for Treatment -
Emergent A bnormality
Selected tests m ay be obtained i n the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th subjects in consultation with Lilly or i ts desi gnee clinical research 
physician .
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrombin time
WBC Prothrombin time, INR
Neutrophils
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis C antibody
Hepatic Chemistry a Hepatitis E antibody, IgG
Total bilirubin Hepatitis E antibody, IgM
Conjugated bilirubin
Alkaline phosphatase
ALT Anti -nuclear antibody a
AST Alkaline phosphatase isoenzymes a
GGT
CPK Anti -smooth muscle antibody (or anti -actin 
antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = asp artate aminotransferase; CPK = creatine phosphokinase; 
GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normalized ratio; RBC = red 
blood cells; WBC = white blood cells.
aAssay ed by Lilly -designated or local laboratory.
bReflex/con firmation dependent on regulatory requirements and/or testing availability .
I6T-MC-AMBE Clinical Pharmacology Protocol Page 52
LY3074828Appendix 5. Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sam pling (screening, safet y laboratori es,and bioanaly tical assays) during the study .  
Protocol I6T-MC-AMBE Sampling Summary
PurposeBlood Volume per 
Sample (mL)Number of Blood 
SamplesTotal Volume 
(mL)
Screening tests a 22.5 1 22.5
Clinical laboratory tests a 12.5 5 62.5
Pharmacokinetics b 2 17 34
Immunogenicity a 10 5 50
Pregnancy tests 3.5 4 14
Pharmacogenetics 10 1 10
Total 193
Total for clinical purposes [rounded up to nearest 10 mL] 200
aAdditional samples may be drawn if needed for safety purposes.
bIncludes a potential 3 additional samples to be matched to additional immunogenicity samples (see 
Section 9.6.1).
P P D L e o  D o c u m e n t  I D  =  6 a 6 9 f 3 1 c - 0 b 0 3 - 4 1 1 5 - 8 f 9 e - f 4 b b 1 e d e 4 f 5 5 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  1 3 - D e c - 2 0 1 8  2 1 : 1 0 : 2 7  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  1 7 - D e c - 2 0 1 8  1 6 : 0 7 : 2 6  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d P P D 